Full Press Release Details
PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47thAnnual Global Healthcare Conference to take place on June 8-10, 2026.
Goldman Sachs 47thAnnual Global Healthcare Conference
| Date / Time: | June 10, 2026, at 8:40 AM ET |
| Format: | Fireside chat and 1x1 investor meetings |
| Location: | Miami Beach, FL |
| Webcast Link: | here |
The webcast from the conference will also be available on UroGen’s corporate website, underEvents & Presentations. A replay will be available for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is approved for adult patients with recurrent LG-IR-NMIBC. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visitwww.urogen.comto learn more or follow us on X, @UroGenPharma.
INVESTORS:
Vincent PerroneSenior Director, Investor Relationsvincent.perrone@urogen.com609-460-3588 ext. 1093
MEDIA: